GPGrossPatternRESEARCH SYSTEM
SEC CHECK OPERATIONAL
GROSSPATTERN / FUNDAMENTAL STATE / POINT IN TIME

NAGE · Mar 31, 2024

Niagen Bioscience, Inc.. A multidimensional configuration derived from the filing available at this observation—never a composite score or recommendation.

STATE CAPABILITYLEVEL 3[email protected]
Inspectable configuration

State dimensions

Filing0001628280-24-021645General Corporate
Operating cash generationRAWCurrent state valid · history insufficient
Evidence method

Ratio · gp.fundamentals.operating_cash_flow + gp.fundamentals.revenue

1.33% · OPTIONAL · NOT_ENOUGH_HISTORY

Revenue growthRAWCurrent state valid · history insufficient
Evidence method

Yoy · gp.fundamentals.revenue

-1.79% · CORE · NOT_ENOUGH_HISTORY

Inventory pressureRAWCurrent state valid · history insufficient
Evidence method

Level · gp.fundamentals.inventory_revenue_ratio

56.40% · OPTIONAL · NOT_ENOUGH_HISTORY

Gross marginRAWCurrent state valid · history insufficient
Evidence method

Level · gp.fundamentals.gross_margin

60.74% · CORE · NOT_ENOUGH_HISTORY

Operating marginRAWCurrent state valid · history insufficient
Evidence method

Level · gp.fundamentals.operating_margin

-3.30% · CORE · NOT_ENOUGH_HISTORY

R&D intensityRAWCurrent state valid · history insufficient
Evidence method

Ratio · gp.fundamentals.rnd + gp.fundamentals.revenue

9.46% · OPTIONAL · NOT_ENOUGH_HISTORY

SBC intensityRAWCurrent state valid · history insufficient
Evidence method

Level · gp.fundamentals.sbc_revenue_ratio

4.44% · OPTIONAL · NOT_ENOUGH_HISTORY

As-filed lineage

Fundamental state history

Each observation is tied to the filing and facts available at that report date. Amendments remain separate.

History17 statesSelf-history eligible
Jun 30, 20220/6 normalizedLevel 3Sep 30, 20220/6 normalizedLevel 3Dec 31, 20220/6 normalizedLevel 3Mar 31, 20230/6 normalizedLevel 3Jun 30, 20230/7 normalizedLevel 3Sep 30, 20230/7 normalizedLevel 3Dec 31, 20230/7 normalizedLevel 3Mar 31, 20240/7 normalizedLevel 3Jun 30, 20246/7 normalizedLevel 3Sep 30, 20246/7 normalizedLevel 3Dec 31, 20246/7 normalizedLevel 3Mar 31, 20256/7 normalizedLevel 3Jun 30, 20257/7 normalizedLevel 3Sep 30, 20257/7 normalizedLevel 3Dec 31, 20256/6 normalizedLevel 3Mar 31, 20267/7 normalizedLevel 3Jun 30, 20267/7 normalizedLevel 4
Period transition

What moved in the state?

Cash Generation Decreased
Previous
8.52%
Current
1.33%
Delta
-7.18%
Growth Decreased
Previous
15.99%
Current
-1.79%
Delta
-17.78%
Inventory Pressure Increased
Previous
17.38%
Current
56.40%
Delta
39.02%
Margin Decreased
Previous
60.76%
Current
60.74%
Delta
-0.02%
Profitability Increased
Previous
-6.70%
Current
-3.30%
Delta
3.40%
R And D Intensity Increased
Previous
5.93%
Current
9.46%
Delta
3.52%
Sbc Intensity Decreased
Previous
5.68%
Current
4.44%
Delta
-1.24%
Self-history only

Previous similar states

Similarity compares compatible valid dimensions from this issuer's own point-in-time history. No market-return claim is attached.

Not enough compatible prior states for a transparent self-history match.
Research Graph

Related governed research

Transitioned To · NAGE Fundamental State →Has State · Niagen Bioscience, Inc. →Transitioned To · NAGE Fundamental State →Transitioned To · NAGE CASH_GENERATION_DECREASED →Transitioned To · NAGE GROWTH_DECREASED →Transitioned To · NAGE INVENTORY_PRESSURE_INCREASED →Transitioned To · NAGE MARGIN_DECREASED →Transitioned To · NAGE PROFITABILITY_INCREASED →Transitioned To · NAGE R_AND_D_INTENSITY_INCREASED →Transitioned To · NAGE SBC_INTENSITY_DECREASED →

Method Percentiles and historical matches use only observations available at each point in time. Missing dimensions remain missing. Public price outcomes and cross-market analogues are deliberately absent.